Press "Enter" to skip to content

Roche: FDA approves drug combo Venclexta plus Gazyva for previously untreated chronic lymphocytic leukaemia

"Venclexta plus Gazyva is the only chemotherapy-free option of fixed duration that provides durable responses to help people live longer", Roche’s Chief Medical Officer Sandra Horning said.

Original source:

Also Read:   EU warns of risks of Covid-19 vaccine race after UK approval of Pfizer shot